Clinical Trials

Phase 1/2 Active not recruiting

5 enrolled 9 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03831932 2026-05-28

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

22 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06303167 2026-05-28

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

LymphoidOther hematologic neoplasmPlasma cell

19 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04487080 2026-05-08

MARIPOSA

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03521154 2026-05-05

LAURA

216 enrolled 25 charts 1 FDA

GastrointestinalGenitourinaryGynecologic

Carcinoma, Non-Small-Cell Lung

NCT06630325 2026-04-28

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Terminated

6 enrolled 3 charts

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03778229 2026-04-23

SAVANNAH

367 enrolled 32 charts

674 enrolled 21 charts 1 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT02296125 2026-04-21

FLAURA

Phase 3 Completed

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT04765059 2026-04-21

COMPEL

98 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT01802632 2026-04-20

AURA

Phase 1/2 Completed

603 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT02511106 2026-03-30

ADAURA

682 enrolled 20 charts 1 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma

NCT03433469 2026-03-30

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

27 enrolled 14 charts

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03381274 2026-03-11

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

43 enrolled 30 charts